Repligen (RGEN) AI Stock Analysis

• Market Cap: $8.58B
• Dividend Yield: N/A
• Average Volume (3M): 934.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: 8.73%
• EPS Growth: -245.82%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 56,257,618
• 10 Day Avg. Volume: 974,763
• 30 Day Avg. Volume: 934,280
• PEG Ratio: 1.84
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 12.69
• P/FCF Ratio: 56.51
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 10.40
• Enterprise Value/Gross Profit: 21.46
• Enterprise Value/Ebitda: 51.68
• 1Y Price Target: $178.23
• Price Target Upside: 16.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 64 Neutral
• Price Target: $156.00 ▲(2.23% Upside)

Repligen's overall stock score reflects strong technical indicators and positive earnings call sentiment, offset by financial performance challenges and valuation concerns. The company's strategic focus on organic growth and improved guidance are significant positives, but profitability issues and a negative P/E ratio weigh on the score.

Positive Factors

Organic Revenue Growth

Strong organic growth indicates robust demand for Repligen's core products, enhancing its market position and supporting long-term revenue expansion.

Chromatography Segment Success

The significant growth in the chromatography segment underscores Repligen's competitive advantage and innovation, driving sustained demand and market leadership.

Positive Financial Guidance

Raising revenue guidance reflects management's confidence in future performance and strategic initiatives, providing a positive outlook for investors.

Negative Factors

Profitability Challenges

Ongoing profitability issues highlight operational inefficiencies, which could hinder Repligen's ability to reinvest in growth and maintain competitive positioning.

Cash Flow Management Issues

Declining free cash flow growth suggests potential inefficiencies in cash management, which could impact Repligen's ability to fund operations and strategic initiatives.

China Market Challenges

Uncertainty in the China market due to tariff issues could limit Repligen's growth prospects in a key region, affecting overall revenue potential.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen generates revenue primarily through the sale of its bioprocessing products and technologies. Key revenue streams include the sale of chromatography resins, filtration products, and other consumables used in biomanufacturing processes. The company also derives income from its services related to product development and customer support. Significant partnerships with leading biopharmaceutical companies enhance its market presence and contribute to its earnings by ensuring consistent demand for its products. Additionally, Repligen's focus on innovation and expansion into new markets helps to drive growth and diversify its revenue base.

Repligen Financial Statement Overview

Summary

Repligen shows a mixed financial performance with strong balance sheet and operational cash flow, but faces challenges in profitability and growth. The company maintains a strong equity position and low leverage, yet needs to address its declining net income and EBIT margins to improve its financial health and investor confidence.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	673.96M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	326.42M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	135.55M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-13.83M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.90B	2.83B	2.83B	2.53B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	708.86M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	686.06M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	839.89M	856.95M	866.34M	620.90M	608.29M	373.74M
Stockholders Equity	2.06B	1.97B	1.96B	1.91B	1.75B	1.53B
Cash Flow
Free Cash Flow	103.81M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	132.11M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.57M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-83.32M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 152.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 152.6 is above the 20-day moving average (MA) of 140.69, above the 50-day MA of 128.59, and above the 200-day MA of 134.89, indicating a bullish trend. The MACD of 7.53 indicates Negative momentum. The RSI at 66.65 is Neutral, neither overbought nor oversold. The STOCH value of 70.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	$4.85B	41.59	8.60%	―	10.14%	0.04%
TFX	73 Outperform	$5.66B	30.16	4.36%	1.06%	1.11%	-23.73%
ATR	72 Outperform	$8.52B	22.31	15.36%	1.39%	1.51%	21.70%
RGEN	64 Neutral	$8.58B	―	-0.68%	―	8.73%	-245.82%
STVN	58 Neutral	$6.67B	45.65	9.55%	0.25%	5.95%	7.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLCO	47 Neutral	$5.31B	―	-4.22%	―	8.81%	40.43%

Repligen Corporate Events

Repligen Appoints Violetta Hughes as Chief Accounting Officer

On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025. This strategic move aims to enhance the company’s financial reporting infrastructure and compliance with the Sarbanes–Oxley Act. Ms. Hughes, a seasoned finance executive with over 25 years of experience, will replace Jason K. Garland, who will continue as the Chief Financial Officer focusing on corporate strategy and growth. Her extensive background in financial governance and SOX compliance is expected to bring significant improvements to Repligen’s financial transparency and strategic decision-making processes.